Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 12/20 | 0.49 |
| ▸ | KIF11 | P52732 | 1/20 | 0.48 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 3/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31492452 | 0.79 | PGR (0.49) | EPHX2PGRKIF11TDP2PDE4A | |
| SCHEMBL17027142 | 0.76 | PGR (0.51) | EPHX2PGRTDP2PDE4APDE4B | |
| SCHEMBL31492425 | 0.76 | PGR (0.51) | EPHX2PGRTDP2PDE4APDE4B | |
| SCHEMBL15649741 | 0.76 | EPHX2 (0.59) | EPHX2PGRMAPK14RAF1NTRK1 | |
| SCHEMBL5959176 | 0.75 | KIF11 (0.43) | PGRKIF11TDP2 | |
| SCHEMBL26460984 | 0.75 | CCR6 (0.63) | — | |
| SCHEMBL30446355 | 0.74 | BACE1 (0.47) | EPHX2PGRKIF11TDP2PDE4A | |
| SCHEMBL5959179 | 0.74 | EPHX2 (0.59) | EPHX2PGRPDE4APDE4BPDE4C | |
| SCHEMBL30898630 | 0.74 | EPHX2 (0.59) | EPHX2PGRPDE4APDE4BPDE4C | |
| SCHEMBL6424665 | 0.71 | PGR (0.67) | PGRPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102198-B1 | SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2015-02-25 | — | — | EP | disclosed |
| US-8173674-B2 | Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-08 | — | — | US | disclosed |
| US-8173674-B2 | Sulfonyl-phenyl-2H-[1,2,4]oxadiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-05-08 | — | — | US | disclosed |
| US-20090298871-A1 | SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | US | disclosed |
| US-20090298871-A1 | SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | US | disclosed |
| WO-2008071311-A1 | SULFONYL-PHENYL-2H-[1,2,4]OXODIAZOL-5-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298871-A1 | SULFONYL-PHENYL-2H-[1,2,4]OXADIAZOL-5-ONE DERIVATIVES , PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | PPARD, PPARG, PPARA | EPHX2 3910/4885PGR 1195/4885KIF11 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.